Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 292 Cr.
- Current Price ₹ 245
- High / Low ₹ 328 / 230
- Stock P/E 16.1
- Book Value ₹ 83.0
- Dividend Yield 0.00 %
- ROCE 26.1 %
- ROE 22.0 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 95.7% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -1.26%
- Company has high debtors of 177 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 5 | 10 | 22 | 32 | 45 | 68 | 102 | |
| 5 | 8 | 19 | 25 | 36 | 50 | 78 | |
| Operating Profit | -0 | 1 | 3 | 6 | 9 | 18 | 24 |
| OPM % | -5% | 13% | 12% | 20% | 20% | 26% | 24% |
| 0 | 0 | 1 | 1 | 2 | 3 | 4 | |
| Interest | 1 | 0 | 0 | 0 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Profit before tax | -1 | 1 | 3 | 7 | 10 | 18 | 25 |
| Tax % | -26% | 26% | -32% | 9% | 28% | 27% | 28% |
| -1 | 1 | 4 | 6 | 7 | 13 | 18 | |
| EPS in Rs | -2.58 | 1.26 | 4.94 | 5.23 | 6.12 | 11.35 | 15.16 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 60% |
| 3 Years: | 48% |
| TTM: | 50% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 96% |
| 3 Years: | 44% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 19% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 20% |
| Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 8 | 12 | 12 | 12 | 12 |
| Reserves | -6 | -5 | -3 | 34 | 41 | 54 | 87 |
| 6 | 5 | 2 | 3 | 6 | 15 | 25 | |
| 3 | 7 | 7 | 7 | 14 | 17 | 36 | |
| Total Liabilities | 6 | 11 | 14 | 56 | 73 | 98 | 159 |
| 1 | 1 | 1 | 3 | 8 | 15 | 29 | |
| CWIP | 0 | 0 | 0 | 0 | 4 | 1 | 0 |
| Investments | 0 | 0 | 0 | 4 | 4 | 12 | 20 |
| 6 | 10 | 12 | 49 | 57 | 70 | 111 | |
| Total Assets | 6 | 11 | 14 | 56 | 73 | 98 | 159 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| -1 | 1 | -0 | -17 | 1 | -3 | 8 | |
| -0 | -1 | -0 | -6 | -11 | -8 | -20 | |
| 1 | -1 | 1 | 36 | 2 | 7 | 14 | |
| Net Cash Flow | 0 | -0 | 0 | 14 | -8 | -4 | 2 |
| Free Cash Flow | -1 | 1 | -1 | -19 | -8 | -9 | -7 |
| CFO/OP | 219% | 118% | -7% | -256% | 37% | 4% | 57% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 97 | 24 | 83 | 140 | 112 | 110 | 177 |
| Inventory Days | 104 | 349 | 95 | 129 | 137 | 167 | 136 |
| Days Payable | 202 | 266 | 134 | 87 | 94 | 97 | 153 |
| Cash Conversion Cycle | -1 | 107 | 44 | 183 | 155 | 180 | 160 |
| Working Capital Days | -12 | 12 | 49 | 274 | 246 | 226 | 192 |
| ROCE % | 34% | 55% | 25% | 19% | 28% | 26% |
Insights
In beta| Mar 2021 | Mar 2022 | Sep 2023 | Jun 2025 | |
|---|---|---|---|---|
| Revenue Break-up: Export % |
|
|||
| Consolidated Manufacturing Capacity: Capsules Million per month |
||||
| Consolidated Manufacturing Capacity: Tablets Million per month |
||||
| Countries presence globally Number |
||||
| Export market product registrations in process Number |
||||
| Export market products registered Number |
||||
| Number of Registered Brands (Trademarks) Number |
||||
| Team Size (Employees) Number |
||||
| Total Products in Portfolio / Product Applications Number |
||||
| Consolidated Manufacturing Capacity: Injectables Million per month |
||||
Extracted by Screener AI
Documents
Announcements
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
1d - Hardik Desai Family Trust disclosed open-market purchase of 10,000 Trident Lifeline shares.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
9 May - Earnings Presentation for the half year and year ended 31st March, 2026 (H2 & FY26).
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 May - In accordance with Regulation 47 and other applicable provisions of SEBI (LODR) Regulations, we hereby enclose copies of newspaper advertisement published on May 09, 2026 …
-
Appointment Of Internal Auditor
7 May - Board approved audited FY26 standalone and consolidated results on 7 May 2026; appointed DAC & Co. internal auditor.
- Result- Financial Result For Half Year And Year Ended On 31.03.2026 7 May
Annual reports
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Jul 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Jan 2023TranscriptAI SummaryPPT
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities